Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
Previous Symbol
CUSIP45337C10
Phone302-498-6700
Debt
Debt-to-Equity Ratio0.01
Current Ratio4.02
Quick Ratio4.01
Price-To-Earnings
Trailing P/E Ratio99.58
Forward P/E Ratio148.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.54 billion
Price / Sales8.83
Cash Flow$0.8392 per share
Price / Cash75.94
Book Value$7.73 per share
Price / Book8.24
Profitability
EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-6.07%
Return on Equity2.23%
Return on Assets1.59%
Miscellaneous
Employees1,208
Outstanding Shares212,810,000
Market Cap$14.05 billion
OptionableOptionable
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported $0.38 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.40 by $0.02. The biopharmaceutical company earned $449.68 million during the quarter, compared to the consensus estimate of $448.34 million. Incyte had a positive return on equity of 2.23% and a negative net margin of 6.07%. The firm's revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter last year, the company posted $0.19 earnings per share. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
23 Wall Street analysts have issued 1 year target prices for Incyte's shares. Their predictions range from $70.00 to $172.00. On average, they anticipate Incyte's share price to reach $95.6728 in the next twelve months. This suggests a possible upside of 50.1% from the stock's current price. View Analyst Price Targets for Incyte.
What is the consensus analysts' recommendation for Incyte?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. Raymond James analysts commented, "We are reiterating our Strong Buy rating for Incyte. This morning, the company announced that the FDA has accepted for priority review its supplemental new drug application (sNDA) for Jakafi for the treatment of patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The priority review grants a 6 month review period by the FDA, resulting in a PDUFA date of approximately March 25, 2019. Based on positive data from the REACH1 study, we remain confident regarding Incyte’s expansion into the steroid refractory GVHD market, which we estimate to be a ~$500 million market opportunity in the U.S." (10/25/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are increasing our price target to $74 from $73 and reiterating our Neutral rating on INCY. At the ongoing ESMO, INCY provided updated Fight-202 results in cholangiocarcinoma, which looked superior to the previously disclosed initial data. Additionally, in a late-breaker presentation, Novartis (NVS, Not Covered) reported Phase II results from its MET inhibitor capmatinib in MET-mutated advanced non-small cell lung cancer (NSCLC) patients. Note that NVS received worldwide rights for capmatinib from INCY. NVS reported promising response rate data that compare favorably to earlier reported results from any MET inhibitors." (10/21/2018)
- 3. According to Zacks Investment Research, "Incyte's Jakafi continues to drive growth propelled by increase in patient demand. Jakafi’s performance is expected to get a further boost with a potential label expansion of the drug. Incyte expects to submit an sNDA seeking approval of Jakafi in patients with steroid-refractory acute graft-versus-host disease in the third quarter of 2018. The recent FDA approval of Olumiant 2 mg is a positive as well as Incyte received a milestone payment from Lilly. However, Incyte suffered a huge setback with failure of the phase III study, ECHO-301, evaluating epacadostat in combination with Keytruda as it was one of the most promising candidates of the company. Further, the approval of the 4mg dose of baricitinib is doubtful. Moreover, Incyte’s dependence on only Jakafi is concerning. Shares have underperformed the industry in the year so far." (10/16/2018)
- 4. JPMorgan Chase & Co. analysts commented, "INCY’s 1Q print/report (initial thoughts here; slides here) this morning was relatively uneventful. Following the success of REACH1 in acute GVHD, management is planning a regulatory filing in 3Q18 (recall Jakafi has BTD status) with plans for an immediate launch upon approval. Also, as previously disclosed, a filing for the FGFR inhibitor in cholangiocarcinoma is still anticipated in 2019, pending final data follow- up (interim data at recent investor day). We’re maintaining our OW given shares are trading at a discount to our DCF derived fair value for the base business. With that said, we suspect it will require some significant execution on the relatively broad pipeline for investors to more actively re-engage with the story." (8/1/2018)
Has Incyte been receiving favorable news coverage?
Media coverage about INCY stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a daily sentiment score of 0.6 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and HedgePath Pharmaceuticals (HPPI).
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
- Mr. David W. Gryska M.B.A., MBA, Exec. VP & CFO (Age 63)
- Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)
Who are Incyte's major shareholders?
Incyte's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.09%), Manning & Napier Group LLC (2.17%), BB Biotech AG (1.79%), Pictet Asset Management Ltd. (0.88%), First Trust Advisors LP (0.73%) and Bank of New York Mellon Corp (0.62%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Institutional Ownership Trends for Incyte.
Which institutional investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Mitsubishi UFJ Trust & Banking Corp, Massachusetts Financial Services Co. MA, Shikiar Asset Management Inc., Exane Derivatives, Hsbc Holdings PLC, Strs Ohio and Prudential Financial Inc.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, David W Gryska, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Vijay K Iyengar. View Insider Buying and Selling for Incyte.
Which institutional investors are buying Incyte stock?
INCY stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, First Trust Advisors LP, BlackRock Inc., Manning & Napier Group LLC, Eaton Vance Management, QCI Asset Management Inc. NY, Panagora Asset Management Inc. and Canada Pension Plan Investment Board. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $63.73.
How big of a company is Incyte?
Incyte has a market capitalization of $14.05 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.
What is Incyte's official website?
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (NASDAQ INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
